Nurses could be key to expanding HIV prevention in rural america
NCT ID NCT07346508
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether nurses, instead of doctors, can safely and effectively give long-acting HIV prevention shots in rural public health clinics. About 250 adults at risk for HIV will take part across several clinics in Missouri. The goal is to see if this nurse-driven approach helps more people access and stay on this prevention method, especially in areas with few healthcare providers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Long-acting injectable cabotegravir (LAI-CAB) for HIV pre-exposure prophylaxis (PrEP)
What this could lead to
If successful, this nurse-driven model could make long-acting HIV prevention widely available in rural and underserved communities, reducing new HIV infections.
What could go wrong
This is an early implementation study, not a large-scale trial, so results may not apply everywhere. The approach depends on nurse training and local resources, which could limit success in other settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV - HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••